TG Therapeutics
TGTX
194 hedge funds and large institutions have $1.91B invested in TG Therapeutics in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 65 increasing their positions, 64 reducing their positions, and 56 closing their positions.
10% more call options, than puts
Call options by funds: $61M | Put options by funds: $55.3M
2.66% more ownership
Funds ownership: 67.5% → 70.16% (+2.7%)
2% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 64
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 222 → 194 (-28)
41% less capital invested
Capital invested by funds: $3.21B → $1.91B (-$1.3B)
45% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$71.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$39.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.7M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$57.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$49M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$42.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$29M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.9M |
TGTX Hedge Fund Activity: Q4 2021 in Review
194 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2021, worth a combined $1.91B — down 41% from $3.21B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of TGTX and 31 opened new positions — a net loss of 25 holders — while 64 trimmed existing stakes and 65 added.
The largest buyer was Maverick Capital, adding an estimated $71.1M. The largest seller was Alkeon Capital Management, cutting an estimated $57.1M.
- 194 institutional investors held TG Therapeutics (TGTX) as of Q4 2021, down from 222 in Q3 2021.
- Funds reported $1.91B of TG Therapeutics stock for Q4 2021, down 41% quarter-over-quarter.
- 31 funds opened new TG Therapeutics positions in Q4 2021 and 56 closed out, a net change of -25 holders.
- The largest TG Therapeutics buyer in Q4 2021 was Maverick Capital, an estimated $71.1M added.
- The largest TG Therapeutics seller in Q4 2021 was Alkeon Capital Management, an estimated $57.1M sold.
Based on aggregated 13F filings for Q4 2021.